Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview

Eunus S. Ali1, Shamima Akter2, Sarker Ramproshad3, Banani Mondal3, Thoufiqul Alam Riaz4, Muhammad Torequl Islam5, Ishaq N. Khan6, Anca Oana Docea7, Daniela Calina8*, Javad Sharifi-Rad9* and William C. Cho10*

Abstract

MAPK (mitogen-activated protein kinase) or ERK (extracellular-signal-regulated kinase) pathway is an important link in the transition from extracellular signals to intracellular responses. Because of genetic and epigenetic changes, signaling cascades are altered in a variety of diseases, including cancer. Extant studies on the homeostatic and pathologic behavior of MAPK signaling have been conducted; however, much remains to be explored in preclinical and clinical research in terms of regulation and action models. MAPK has implications for cancer therapy response, more specifically in response to experimental MAPK suppression, compensatory mechanisms are activated. The current study investigates MAPK as a very complex cell signaling pathway that plays roles in cancer treatment response, cellular normal conduit maintenance, and compensatory pathway activation. Most MAPK inhibitors, unfortunately, cause resistance by activating compensatory feedback loops in tumor cells and tumor microenvironment components. As a result, innovative combinatorial treatments for cancer management must be applied to limit the likelihood of alternate pathway initiation as a possibility for generating novel therapeutics based on incorporation in translational research. We summarize current knowledge about the implications of ERK (MAPK) in cancer, as well as bioactive products from plants, microbial organisms or marine organisms, as well as the correlation with their chemical structures, which modulate this pathway for the treatment of different types of cancer.

Keywords: Cancer, MAPK (ERK), Ras signaling, Ras oncogenes, Molecular mechanisms, Natural bioactive compounds, Chemoresistance, Chemoprevention

Introduction

Cancer is the abnormal and anarchic development of cells, with the potential to invade or spread to various parts of the body [1, 2]. Cancer can occur in any part of the body, and cancer cells can invade other organs in different ways (neighbourhood invasion, hematogenous or lymphatic) [3–5]. In 2020, there have been an estimated 18.1 million cancer cases worldwide. Men accounted for 9.3 million of the cases, while women accounted for 8.8 million. Because of recent advances in novel therapeutics, the diagnosis rate has been increasing in recent years, which has improved the
general life expectancy for patients [6, 7]. Each cancer type can be subdivided now based on mutations of several genes with the aid of advances in molecular diagnostics [8–10], indicative of the molecular patterns that are malfunctioning. Consequently, this allows effective intervention with tailored treatments by blocking certain biological processes of tumor cells which allows effective interference with targeted therapeutics by impeding specific biological pathways of tumor-infected cells [9, 11]. Cancer is frequently associated with the number of mutations that interrupt the key signaling pathways [12–14]. Cellular signaling pathways are organized as modular networks that communicate in real-time [15, 16]. Pathway components work together in a switch-like fashion, with interactions between two proteins that result in either indirect or direct inhibition or activation of the next factor [17–20]. The pathogenesis of numerous signaling pathways is maintained by transcriptomic, epigenetic, and genetic changes [21, 22].

Nowadays, molecular diagnostic tools became more widely available in clinical settings and that help identifies specific mutational patterns of cancer [23, 24]. Subsequently, this condition becomes an effective method for identifying patients with similar alterations, which was used to determine effective treatment modules [22, 25, 26]. Despite this progress, resistance to cancer therapy remains the main issue i.e., common side effects in patients who have received first-line treatment. Targeted therapy, which employs a variety of small molecules that play a role as inhibitors for the key signaling stages, can result in resistance in a few instances even from first doses. Resistance develops as a consequence of tumor cells being positively designated for mechanisms that can compensate for the specifically targeted pathway [18, 27, 28].

Cancer cells have a low dependence on external proliferative stimuli and often do not need such stimulation to multiply; through the mutations of some oncogenes, these cells acquire a proliferative autonomy, producing their mitogenic signals [29]. One of the key characteristics of cancer cells is probably their ability to permanently stimulate their growth and proliferation [30]. To understand this property, it is useful to remember that normal cells need the growth and division of external mitogenic signals (mainly represented by growth factors), produced (in a diffusible form) by other cells (paracrine signaling). These molecules (ligands) bind to specific transmembrane receptors, which, after activation, transmit the signal—through branched intracellular signaling pathways—to the nucleus, triggering division. The whole process is regulated by negative feedback mechanisms, which attenuate excessive proliferative signaling (make it transient) and, if it persists, induce cell senescence and apoptosis [31].

Cancer cells have a low dependence on external proliferative stimuli and often do not need such stimulation to multiply; through the mutations of some oncogenes, these cells acquire a proliferative autonomy, producing their mitogenic signals [24, 32]. The major strategies used by tumor cells to achieve proliferative independence are as follows:

- Production of their growth factors, to which they respond by proliferation (autocrine signaling) (for example, TGF-α in sarcomas) [33]
- Disorder of growth factor receptors, which transduce proliferative signals inside the cell; Disorder involves either overexpression of receptors in many cancers (e.g., amplification of the HER2/neu receptor in about 30% of breast cancers or EGFR in non-small cell lung cancer) or alteration of their structure, which results in receptor activation and therefore signaling, without ligand (for example, truncated version of EGF receptor) [34]
- Alteration of the components of cytoplasmic signaling pathways, which produce a flow of mitogenic signaling without their stimulation by receptors; for example, the mitogen-activated protein kinase pathway, which consists of RAS → RAF → MEK → MAPK → ERK → FOS proteins, plays a central role in about 25% of human cancers [35].

In addition to their ability to intensely stimulate their growth and proliferation (by activating oncogenes), cancer cells are insensitive to signals that could stop cell division. In normal tissues, multiple antiproliferative signals act, external or internal, which maintain tissue homeostasis [36]. Exogenous inhibitory signals—either soluble (TGF-β) or embedded in the extracellular matrix and the surface of neighbouring cells (by cadherin-like adhesion molecules, which cause “contact inhibition”) 2—are received by transmembrane receptors coupled with intracytoplasmic circuits. Signaling, which blocks cell division. Cells move from the postmitotic G1 stage to the resting G0 phase, from where they can return to the cell cycle—when conditions allow—or permanently give up division and differentiate into specific cells [37].

Complex like MAPK is one compound that linked signaling cascade with frequent participation in tumor development, oncogenesis, and resistance of the drug [38, 39]. The MAPK family includes a large number of kinases that are altered in cancer and for which several targeted therapies have been developed [40]. Resistance to MAPK inhibitors is a current issue, owing to the high degree of interactions and perhaps compensating
responses. Thus, in this review, we look at the many repercussions of MAPK pathways in cancer, with a specific emphasis on tumor signaling regulation via MAPK interaction with critical signaling pathways in pathological situations [8]. The current review will concentrate particularly on the pathways of the canonical primary signal transduction depicted in Fig. 1.

**Review methodology**
This review has been based on the use of several databases such as PubMed/Medline, Web of Science, TRIP Database, and Up-to-Date using for searching the next MeSH terms: “Antineoplastic Agents/pharmacology”, “Biological Products/chemistry”, “Biological Products/therapeutic use”, “Cell Line”, “MAP Kinase Signaling
System/drug effects”, “Extracellular Signal-Regulated MAP Kinases/metabolism”, “Mitogen-Activated Protein Kinase Kinases/antagonists and inhibitors”, “Mitogen-Activated Protein Kinase Kinases/metabolism”, “Neoplasms/drug therapy”, “Neoplasms/metabolism”, “Neoplasms/pathology”, “Plants/chemistry”, “Proto-Oncogene Proteins p21(Ras)”, “Signal Transduction/drug effects”, “Ras Proteins/antagonists and inhibitors”, “Ras Proteins/metabolism”, “Xenograft Model Antitumor Assays”.

The study included papers published in English that contained molecular pharmacological data on the anticancer action of the phytochemicals mentioned in our study, studies with broad therapeutic perspectives of application, and studies with a high rate of citations. Studies published in languages other than English, studies without obvious pharmacological mechanisms, and studies that included homeopathic preparations as complementary treatment were excluded.

Ras-ERK and natural bioactive compounds in chemotherapy and chemoprevention: structure—activity relationship and experimental evidence

Phytochemicals and similar derivative compounds have been shown to play an essential role as cancer treatment agents [2, 41–43]. The majority of protein kinase inhibitors found in plants are flavonoids, which are polyketides. Anthraquinones and anthrones, which contain representatives such as hypericin and emodin, are also part of this chemical group. Both compounds have been shown to inhibit protein kinases like CK2 and p65lck [44]. With alkaloids, most of the flavonoid group are valuable “folk medicine” effective for a variety of ailments other than cancer. However, even when proved to be beneficial in the treatment of cancer, various mechanisms other than intervening with protein kinases have been reported [45, 46].

The extracts of wine polyphenol inhibit the cell cycle progression, cause apoptosis via the caspase activation, and alter the activity of the metalloproteinase (MMP) enzyme. Resveratrol, which is stilbene present in lots of foods including red wine grapes, is thought to provide several health advantages. Protein kinases including MEK/ERK1/2, AKT, RAF, JNK and CamKK, have been demonstrated to be inhibited by it. As a result, it is tempting to infer that the reported “anticancer effects” are due to interfering with the different protein kinases. However, considering the modest levels of resveratrol absorbed by wine intake, this may be more apparent than genuine. Even consuming the ultra-pure resveratrol component should not be enough to have a discernible influence on the activity of cellular protein kinase. Furthermore, considering the relatively high number of distinct protein kinases that are affected by resveratrol, it is impossible to rule out unfavourable side effects when significant doses are used.

A similar argument may be made for the other natural chemicals discussed in this review. An example: secondary metabolites include alkaloids, which are mostly constituted of nitrogen and are commonly employed in medicine [47]. Alkaloids are one of the most diverse classes of natural chemicals, with over 12,000 known structures. The ability of the secondary plant metabolites to inhibit the expression of both non-coding and coding genes is then used to modulate a variety of cellular pathways, including MAPK [48, 49]; Table 1 contains several examples.

For the suppression of cell proliferation in pancreatic cells, the NF-κB and MAPK survival pathways were empirically suppressed using CAPE (caffeic acid phenetyl ester) and U0126. CAPE only activated the apoptosis mechanism after autophagy was inhibited [48, 50]; in MIAPaCa-2 cells, this occurred in a caspase-dependent fashion, but in PANC-1 cells, it occurred in a caspase-independent mode [51]. CAPE is a complicated therapeutic agent that affects not only programmed cell death but also angiogenesis and EMT pathways [52]. Furthermore, this study emphasizes the significance of selecting the appropriate cell culture model and understanding the characteristics of the cell lines to collect meaningful results [51].

Apigenin, a flavonoid is another chemopreventive drug that suppresses the development of choriocarcinoma cells by regulating the ERK1/2 MAPK and PI3K/AKT signal transduction mechanisms. The presence of ERK1/2 inhibitors and PI3K/AKT inhibitors enhances these effects [53].

Kaempferol, another flavanol, has been linked to angiogenesis inhibition by affecting HIF-1 and VEGFR2 in endothelial cells via a process involving PI3K/AKT/mTOR and ERK/p38. Endothelial cells were treated with kaempferol in combination with a p38 inhibitor (SB203580) or an ERK inhibitor (PD98059), and the therapeutic effectiveness of kaempferol was found to be enhanced [88].

Coumestrol, phaseol, and isoflavonol have been shown significant anti-inflammatory effects on LPS (Lipopolysaccharide)-induced RAW264.7 macrophages, mostly via TLR/MAPK signaling and TLR (Toll-like receptors)/NF-κB [89]. Coumestrol, a phytoestrogen, inhibits cell proliferation through modulating MAPK-related genes and an AKT-related compensatory mechanism [54]. Quercetin, a flavonol molecule found in high concentrations, has been shown to inhibit choriocarcinoma growth by interfering with
| Natural compounds                  | Type of cancer                  | Preclinical Model In vitro/cancer cell lines | Molecular targets                                                                 | Effects                                                                 | Refs.  |
|-----------------------------------|---------------------------------|---------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------|--------|
| Caffeic acid phenethyl ester (CAPE) | Pancreatic ductal adenocarcinoma | PANC-1 MIAPaCa-2                           | ↓ NF-κB, ↓ MAPK                                                                    | Cell growth, ↑ Apoptosis (PANC-1 caspase-independent mode and MIAPaCa-2 caspase-dependent) | [51]   |
|                                  | Choriocarcinoma                 | JEG3 JAR                                    | ↓ ERK1/2, ↓ P38/AKT                                                                | Migratory capacity, ↓ Cell viability, ↑ Apoptosis                     | [53]   |
|                                  | Prostate cancer                 | LNCaP PC3                                   | ↓ Phosphorylation of AKT proteins, ↑ Phosphorylation of p90RSK, JNK, ERK1/2, p53 | Cell proliferation, ↓ migration, ↑ apoptosis                          | [54]   |
|                                  | Choriocarcinoma                 | JEG3 JAR                                    | ↑ Phosphorylation of p38, JNK, ERK1/2, and p90RSK proteins                          | Proliferation, ↓ Invasion, ↓ Cell-cycle progression                   | [55]   |
|                                  | Endometrial Malignant transformation | EBM-2 HUVECs                               | ↑ VEGFR2, ↓ HIF-1α proteins, ↓ Phosphorylation of and p38, ↓ ERK, ↓ Akt           | Angiogenesis                                                           | [56]   |
|                                  | Melanoma                        | B16F10                                      | ↓ ERK, ↓ p38, ↓ JNK, ↓ Phosphorylation of tensin-2, ↓ FAK, ↓ paxillin, ↓ vinculin | Cells growth, ↓ Cells migration                                       | [57]   |
|                                  | Endometrial cancer              | RL-95–2 ECC-1 cells                         | ↑ Phosphorylation of S6 only in RL-95–2 cells, ↑ Phosphorylation of the p42/44 in both cell line | Cellular proliferation, ↓ Cell-cycle arrest in G2 phase, ↑ Autophagy, ↑ Apoptosis | [58]   |
|                                  | T-cell acute lymphoblastic leukemia | Jurkat (glucocorticoid resistant) and T-ALL cell lines, Molt-4 (glucocorticoid resistant) | ↑ p38-MAPK, ↓ Akt/p70S6K/mTOR/4E-BP1                                              | Autophagy, ↑ Apoptosis                                                | [59, 60] |
|                                  | Osteosarcoma                    | MNNG, MG-63, Saos-2, U-2OS                 | ↑ p38                                                                               | Autophagy, ↑ Apoptosis                                                | [61]   |
|                                  | Lung cancer                     | A549                                        | ↓ ERK, ↓ p-JNK, ↓ p-ERK, ↓ p38, ↓ JNK, no effect on p-38                            | Targeting drug resistance via P-glycoprotein (P-gp)/MDR1-associated resistance | [62]   |
|                                  | Lung cancer                     | H1975 and A549 cells                       | ↓ Snail, ↓ TGFβ1, ↓ Phosphorylation of ERK                                         | Prevents TGFβ1-induced EMT and invasion, migration, and adhesion      | [63]   |
|                                  | Cervical cancer                 | Hela cells                                  | ↑ Fas, ↑ phospho-JNK, ↑ p53, ↑ phospho-p38, ↑ Bax, ↓ PAR2, ↓ mTOR, ↓ Bcl-2        | Cellular proliferation, ↑ Apoptosis                                  | [64]   |
### Table 1 (continued)

| Natural compounds | Type of cancer            | Preclinical Model In vitro/cancer cell lines | Molecular targets | Effects                  | Refs. |
|-------------------|---------------------------|---------------------------------------------|-------------------|--------------------------|-------|
| Baicalein         | Hepatocellular carcinoma  | HepG2 cell xenograft in nude mice           | ↓ MEK1            | ↑ Intrinsic apoptosis    | [65]  |
|                   |                           |                                             | ↓ Bad             |                          |       |
|                   |                           |                                             | ↓ ERK1/2          |                          |       |
| Fisetin           | Laryngeal cancer          | TU212 cell                                  | ↓ RAS             | ↓ Cell migration         | [66]  |
|                   |                           |                                             | ↓ RAF             | ↓ Proliferation          |       |
|                   |                           |                                             | ↓ ERK1/2          |                          |       |
| Naringenin        | Prostate cancer           | LNCaP and PC3 cells                         | ↓ p38 ERK1/2,    | ↑ Apoptosis, ↑ ROS       | [67]  |
|                   |                           |                                             | ↓ S6              | ↑ Proliferation, ↓ Migration |       |
|                   |                           |                                             | ↓ P70S6K, ↓ JNK   |                          |       |
| Silibinin         | Hepatocellular carcinoma  | Bel‑7404 xenografts in nude mice            | Combined treatment with the sorafenib | Proliferation ↑ Apoptosis | [68, 69] |
|                   |                           |                                             | ↓ Phosphorylation of ERK, STAT3, AKT, MAPK p38 |                |       |
| Taxifolin         | Skin cancer               | skin carcinogenesis mouse model, ββ6 mouse skin epidermal cells | ↓ Phosphorylation of p38, EGFR, ERKs, JNKs | ↓ Tumor incidence, ↓ Multiplicity in a solar UV (SUV)-induced skin carcinogenesis | [70] |
| Delphinidin       | Osteosarcoma              | HOS, U2OS, MG-63 cells                      | ↓ Phosphorylated forms of p38 | ↓ Cell migration ↓ EMT ↓ Apoptosis ↑ Apoptosis | [71] |
|                   |                           |                                             | ↓ ERK              |                          |       |
| Parthenolide      | Non-small cell lung cancer| GLC‑82 cells                                | ↓ c-Myc, ↓ B-Raf, | ↓ Invasion ↑ Apoptosis    | [72, 73] |
|                   |                           |                                             | ↓ Phosphorylation of Erk, MEK, |                          |       |
| Oridonin          | Esophageal cancer         | KYSE‑150 c xenograft KYSE‑150 cancer nude mice | ↓ Ras/Raf/MEK/ERK | ↓ Tumor angiogenesis ↑ Apoptosis | [74] |
|                   |                           |                                             | ↓ EGFR-mediated PISK/AKT |                |       |
| Curcumin          | Lung and pancreatic adenocarcinoma | p534, H1299, PC-14, Panic1 | ↓ Erk1/2 | ↓ Survival of cancer cell ↑ Apoptosis | [75] |
| Natural compounds     | Type of cancer             | Preclinical Model                  | Molecular targets                                                                 | Effects                                      | Refs. |
|----------------------|----------------------------|------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------|-------|
| Licochalcone A       | Human gastric cancer       | BGC-823 In vitro/cancer cell lines | † JNK, † ERK, † p38 MAPK                                                          | † Oxidative stress                           | [76]  |
| Pterostilbene        | Breast cancer              | MCF-7 MDA-MB-231                    | ↓ Akt, ↓ ERK1/2                                                                   | ↑ Apoptosis, ↓ Proliferation                  | [77]  |
| Arctigenin           | Gallbladder cancer         | GBC-SD, NOZ GBC-SD                  | ↓ EGFR, ↓ p-b-Raf, ↓ p-c-Raf-MEK, ↓ ERK, ↓ MEK, ↓ p-AKT, ↓ AKT                   | † Cancer senescence                          | [78]  |
| α-mangostin          | Cervical cancer            | SiHa and HeLa cells and xeno-graft model | ↑ p-ASK1, p-p38, p-MKK3/6                                                        | ↑ Apoptosis                                  | [79]  |
| Vitisin A            | Pro-tumorigenic inflammation | RAW 264.7 cells                     | ↓ p38, ↓ ERK, ↓ NF-κB                                                            | ↓ Proliferation                              | [80]  |
| Azaspirene           | Renal carcinoma            | Renal carcinoma xenograft model HUVEC | ↓ Raf-1                                                                           | ↓ Angiogenesis                               | [81]  |
| Rocaglamide          | Leukemia                   | Jurkat leukemic cells               | ↓ Raf-MEK-ERK                                                                    | Targeting prohibitin 1 and 2                | [82]  |
Table 1 (continued)

| Natural compounds   | Type of cancer | Preclinical Model | Molecular targets | Effects | Refs. |
|---------------------|----------------|-------------------|-------------------|---------|-------|
| L-783277            | Human pancreatic cancer | PSN1            | ↓ Phosphorylation of Ras-dependent MAP kinase | ↓ Proliferation | [83]  |
| Magnolin            | Non-small cell lung carcinoma | NCI-H1975 A549 | ↓ ERK/RSK2       | ↓ NF-kB | [84]  |
| Tomatidine          | Sarcoma         | HT1080            | ↓ ERK            | ↓ p38, ↓ ERK | Modulation of gelatinase | [85]  |
| Catechol            | Lung cancer     | H460              | ↓ ERK2           | ↑ c-Myc degradation, ↓ ERK2 | [86]  |
| 1,2,3-Triazole Curcumin | Non-small cell lung carcinoma | A549            | ↓ NF-κB/STAT3    | ↑ mitogen-activated protein kinases | ↓ Cell proliferation | [87]  |

↑ increase, ↓ decrease, ROS reactive oxygen species; T-ALL T-cell acute lymphoblastic leukemia; HIF Hypoxia-inducible factors; JNKs c-Jun N-terminal kinases; TGFβ transforming growth factor-beta; ERK extracellular regulated MAP kinase; p38 p38 kinase; AKT v-akt murine thymoma viral oncogene homolog 1; VEGFR vascular endothelial growth factor

PI3K and MAPK signal transduction. Furthermore, quercetin enhanced the chemotherapeutic effects of paclitaxel and cisplatin in the cell lines of choriocarcinoma (JEG3 and JAR) [55].

Isoflavones were recently thought to be promising anticancer medicines [90]. The consequences of genistein and novasoy were studied in endometrial cancer cells. These cells were found to have an antiproliferative impact associated with the activation of the MAPK and AKT/mTOR signaling pathways [58]. Furthermore, it has been established that genistein can reduce ER expression while increasing PR (progesterone receptor) expression [58]. In melanoma cells, genistein inhibits the proliferation of cells, migration and invasion, via the MAPK and FAK/paxillin pathways [57]. Furthermore, 5,6,7,3′,4′,5′-hexamethoxyflavone which is a polymethoxyflavone has been demonstrated to impede the cellular proliferation of triple-negative breast cancer (through MAPK/AKT targeting) and cell-cycle arresting [91].

Resveratrol is a controversial natural chemical with anti-tumour properties that is being investigated as a possible treatment possibility [92]. Resveratrol can preferentially trigger autophagy and apoptosis in the T-cell acute lymphoblastic leukaemia cells via suppression of mTOR/AKT/4E-BP1/p70S6K and initiation of p38-MAPK pathways [93].

Escin, a combination of triterpene and saponins derived from the Aesculus hippocastanum, has anti-tumor ability via autophagy and apoptosis regulation via ROS/p38 MAPK signaling [94].

Furthermore, 21-methylmelianodiol (21-MMD) obtained from Poncirus trifoliata, has anti-tumor effect in the cancer of the lung via interfering with MAPK signaling and AKT/ PI3K/AMPK signaling it is also related to multi-drug resistance reversal by reducing the expressions of P-gp/MDR1 (P-glycoprotein/multidrug resistance protein 1) [95].
Toosendanin is a natural insecticide that has been shown in lung cancer models to switch EMT markers expression via ERK/Snail signaling pathway [96].

Sulforaphane (SFN) is another natural chemical that has been studied for its potential use in the treatment of OS (osteosarcoma) [97]. This isothiocyanate chemical is derived from vegetables such as broccoli, Brussels sprouts, and cabbage. Sawai et al. examined the effects of SFN on the cell line of murine osteosarcoma (LM8). These cells were grown with SFN at various doses, which caused improved cell populations in the phase of G2/M. The combination of 2 Gy of radiation and SFN inhibited the phosphorylation of ERK and AKT. SFN was also shown to cause apoptosis via G2/M phase arrest and to decrease ERK and AKT activation [98]. Another study found that SFN caused genomic instability in the cell lines of MG63 OS by mitotic and nuclear abnormalities, clastogenicity and DNA breaks. Increased production of micronuclei and apoptotic bodies indicated viability loss. SFN might be an effective molecular targeting chemotherapeutic drug for ovarian cancer [99].

Figure 2 depicts some of the most essential areas of action of those natural chemicals and Table 1 presents the most representative chemical structures of bioactive compounds which modulate the Ras-ERK cascade.

Natural bioactive compounds as kinase inhibitors
Plants have a vast store of natural bioactive compounds with beneficial effects on human health [46, 100–102]. According to one study, 80% of the world’s population still uses plant-derived medications to meet their healthcare needs [45, 103, 104]. Traditional medicine utilizes a combination of many ingredients; however, the ingredients might not show activities as a single entity but sometimes a combination of ingredients plays an important role in having synergistic effects and modulating other proteins which improve the efficacy of the bioactive principle [105–107]. Protein kinase inhibitors have recently been shown to be chemically linked to a class of plant chemicals known as sesquiterpenes, alkaloids, flavonoids, polyphenolics, and diterpenoids, which are present in a variety of fruits, vegetables, and medicinal plants and have anti-cancer properties [44, 108]. The FDA authorized 1453 new chemical entities in 2013 with natural products or analogues of natural substances accounting for 40% of the total [109].

DLW (Danggui Longhui Wan) is a common traditional Chinese herbal medicine to treat chronic myeloid leukemia (CML) [110]. It’s made up of eleven different plant ingredients. Only indirubin was shown to be effective against CML during the hunt for the active chemical. The other ten compounds were all inactive. Indirubin is an effective inhibitor of CDKs (cyclin-dependent kinases), which are important in cell division. Because tumor cells rely largely on cell division, inhibiting CDKs will prevent cell division progression and therefore tumor development. Indirubin, on the other hand, performed well but was hard to absorb in the digestive system [111]. Gliotoxin is a sulfur-containing mycotoxin generated by a pathogenic fungus such as Aspergillus fumigatus that inhibits Ras protein and hence cell development [112]. Magnolin, a natural chemical present in Magnolia flos, inhibits cell proliferation caused by tumor promoters such as EGF (epidermal growth factor) and focuses on ERK1 and ERK2 [113].

Discussions
There is proof that the usage of natural compounds originating from microbes, animals, or plants for medical purposes goes back to the Neanderthal epoch [114, 115]. People have gathered knowledge and become an expert in their applications due to various biological activities of isolated natural items [116–118]. The invention of the chemical structure aided the manufacturing of the essential compounds rather than separating them from natural sources [119]. This process was also less expensive and allowed for the use of the active element of the medicinal plant rather than the basic plant extraction [106, 107]. Marketed medications like camptothecin, artemisinin, maytansine, lovastatin, penicillin, paclitaxel, silibinin and reserpine were either indirectly or directly developed from natural compounds [120]. Natural goods are now being viewed as a viable substitute for manufactured medications. These natural compounds can be found in a variety of sources, including plants, microbes, and fungus [118]. Today, pharmaceutical research is shifting away toward multiple target approaches than single-molecule target techniques.

Natural products have been shown to initiate apoptosis and chemosensitive cell lines that were previously resistant to conventional treatments [121–123]. The heterogeneity of natural compounds’ inefficiency found in the cell line-centred tests and rodent models used throughout the phase of the drug discovery, which leads to the ultimate effectiveness in patients, is a significant barrier in the creation of a particular inhibitor [124].

Since the first kinase inhibitor was developed in the 1980s, more than 40 kinase inhibitors have been approved by the FDA for the treatment of malignant cells such as lung and breast cancer cells. Furthermore, around 150 kinase-targeted medicines are in clinical trials, and preclinical research is also going on numerous kinase-specific inhibitors [125]. Despite the promising anti-tumour activity and survival improvements
Fig. 2 Depiction of some of the bioactive natural products and their important areas of action in the Ras-ERK cascade.
gained by licensed RAF, MEK, and ERK inhibitors, drug resistance is the main limitation of the development of new MAPK pathway inhibitors [125]. The underlying processes, which are often associated with genomic instability and cancer heterogeneity, are largely associated with the compensatory initiation of the upstream component. More research into the MAPK pathway has led to the hypothesis that targets the downstream kinase of the ERK, and also the combination of ERK inhibition with MEK and RAF inhibition may be advantageous [125].

B-Raf is in therapeutic use among a few serine/threonine kinases inhibitors. These inhibitors of serine/threonine kinase for MAPK Aurora kinases, and CK2 and mTOR are being developed for therapeutic use [126]. We concentrated on the pathways of the canonical primary signal transduction depicted in Fig. 1. The emphasis is primarily on natural products made from plant sources, particularly flavonoids. Protein kinase B, cyclin-dependent kinases, polo-like kinase I, and other enzymes are affected. CDKs have also been targeted using natural chemicals derived from sources other than plants, such as marine creatures. New microorganisms that can survive in extreme environmental conditions called "extremophiles" have opened new perspectives in the biotechnology/pharmaceutical industry with anti-cancer therapeutic potential by blocking the cell cycle. They also have antioxidant effects. It has been observed that most extremophilic microorganisms have an increased resistance to ultraviolet radiation and can be used to develop anticancer drugs [127]. This might be a new source for developing more strong kinase inhibitors.

**Limitations and future perspectives**

This review has some limitations that need to be addressed in the future, such as the lack of in vivo studies that provide mechanistic perspectives on molecular interactions and targets of action of phytochemicals included in this study. Also, future in silico studies such as molecular docking may address molecular targets for a better understanding of phytochemical interactions in different signaling pathways.

Another limitation is the lack of large-scale and well-controlled clinical trials to validate the efficacy of these molecular targets, their adverse effects, and the safety of their administration for the treatment of cancer.

Although natural products show excellent results in vitro, the development of cytostatic drugs in them is a complex process, except for a few. The therapeutic advantage of these natural products is their minimal toxicity and reduced side effects [92, 128, 129]. But natural bioactive compounds can interact with many proteins, which is why it is very important to elucidate the mechanisms of action of natural products, especially those that are used in our diet [130].

In recent decades, kinase inhibitors have received more attention in search of new drugs and bioactive natural compounds that target a wide range of kinases. However, there are some therapeutic limitations of natural bioactive compounds, such as poor solubility, complexity, and biodisponibility [131–133]. Therefore, to overcome these clinical pitfalls and to obtain food supplements officially approved by the competent authorities, a comprehensive quality analysis must be performed in terms of bioavailability, efficacy, safety, composition, technological manufacturing processes, pharmaceutical regulatory practices and compliance with international standards.

**Conclusion**

At the time, too many diverse biological features are known, making it easy to infer that they are to blame for the reported health impacts. Each ingredient in plant extracts is not effective enough to account for success-ful cancer treatment on its own. There is a growing body of evidence that protein kinase inhibitors can be isolated from sources other than plants. Protein kinase inhibitors have recently been obtained from marine sources. This is a novel and promising strategy for discovering new forms of kinase inhibitors. However, there are a lot of other factors, such as genetics, environment, physical activity, dietary habits, and so on, and food-related considerations alone are insufficient. When a specific molecule would be targeted, which may pave the door for larger use of flavonoids, simply because they interfere with multiple cellular ‘war fields’. When employed appropriately, this finding might lead to an effective anticancer treatment in the future.

**Author contributions**

ESA, SA, SR, BM, TAR, MTI, INK, AOD, DC, JSR, WCC made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas—that is, revising or critically reviewing the article, giving final approval of the version to be published, agreeing on the journal to which the article has been submitted, and confirming to be accountable for all aspects of the work. All authors contributed equally, have read and agreed to the published version of the manuscript. All the authors have read and approved the final manuscript.

**Funding**

No funding received.

**Availability of data and materials**

Yes.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.
Consent for publication
Not applicable.

Competing interests
No competing interest.

Author details
1 College of Medicine and Public Health, Flinders University, Bedford Park 5042, Australia. 2 Department of Bioinformatics and Computational Biology, George Mason University, Fairfax, VA 22030, USA. 3 Department of Pharmacy, Ranada Prasad Shaha University, Narayangang 1400, Bangladesh. 4 Department of Pharmacology and Institute of New Drug Development, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea. 5 Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh. 6 Institute of Basic Medical Sciences, Kyber Medical University, Peshawar 25100, Pakistan. 7 Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. 8 Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. 9 Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador. 10 Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.

Received: 29 March 2022   Accepted: 27 July 2022

Published online: 08 August 2022

References
1. Sel S, Nicolini A, Ferrari P, Biava PM. Cancer: a problem of development biology: scientific evidence for reprogramming and differentiation therapy. Curr Drug Targets. 2016;17(10):1103–10.
2. Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Dash G, Adetunji J. Advances in the pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxid Med Cell Longev. 2022;2022:8615242.
3. GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risks, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022. https://doi.org/10.1016/S2468-1253(22)00044-9.
4. Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev. 2018;54(1):18–21.
5. Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, Adetunji J. Advances in the pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxid Med Cell Longev. 2022;2022:8615242.
6. Docea AO, Mitrut P, Grigore D, Pirici D, Calina DC, Gofita E. Immuno-histochemical expression of TGF beta (TGF-beta), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. J Morphol. 2012;12(3):683–92.
7. Braicu C, Buse M, Busuocor D, Drula R, Gulei R, Radul D, Rusu A, Irimie A, Atanasov AG, Slaby O. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10):1618.
8. Cainap C, Nagy V, Seicean A, Gherman A, Laszlo I, Lisencu C, Nadim AH, Constantin A-M, Cainap S. Results of third-generation epirubicin/cisplatin/axoloid adjuvant chemotherapy in patients with radically resected gastric cancer. J BUON. 2016;21:349–59.
9. Jain D, Chaudhary P, Varshney N, Bin Razzak KS, Verma D, Zhaha TRK, Janmela P, Sharifi-Rad J, Dastan SD, Mahmoud S, et al. Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis. J Oncol. 2021;2021:11.
10. Mitrop M, Docea AO, Kamal AM, Mitrop R, Calina D, Gofta E, Padureanu V, Gruia C, Streba L. Colorectal cancer and inflammatory bowel disease. Houston: Intech; 2016.
11. Dhyan P, Quispe C, Sharma E, Bahukhandi A, Sati P, Atri DC, Szopa A, Sharif-Rad J, Docea AO, Mardare I, et al. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int. 2022;22(1):206.
12. Semwali P, Painuli S, Abu-Izneid T, Rauf A, Sharma A, Dajtan SD, Kumar M, Alshehri MM, Taheri Y, Das R, et al. Diosgenin: an updated pharmacological review and therapeutic perspectives. Oxid Med Cell Longev. 2022;2022:1035441.
13. Zijlstra A, Von Lenser A, Yu D, Bonrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, et al. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin Exp Metastasis. 2019;36(4):305–9.
14. Buga AM, Docea AO, Albu C, Malin RD, Branisteau DE, Ianosi G, Ianosi SL, Iordache A, Calina D. Molecular and cellular stratagam of brain metastases associated with melanoma. Oncol Lett. 2019;17(5):4710–7.
15. Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, Baba Y. Acridic extracellular microenvironment and cancer. Cancer Cell Int. 2013;13(1):89.
16. Plotnikov A, Zehori E, Procaccia S, Seger R (2011) The MAPK cascades signaling components, nuclear roles and mechanisms of nuclear translocation. Biochem Biophys Acta Mol Cell Res. 1813:9:1619–33.
17. Liu F, Yang X, Geng M, Huang M. Targeting ERK, an Achilles’ heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018;8(4):552–62.
18. Ali ES, Rychkov GY, Barratt CJ. Targeting Ca2+-signaling in the initiation, promotion and progression of hepatocellular carcinoma. Cancers (Basel). 2020;12(10):2755.
19. Sutoo S, Maeda T, Suzuki A, Kato Y. Adaptation to chronic acid extracellular pH elicits a sustained increase in lung cancer cell invasion and metastasis. Clin Exp Metastasis. 2020;37(1):133–44.
20. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadou S, Liu DL, Kanthis S, Haghafnia S. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321–337. e310.
21. Seles M, Hutterer GC, Kiesslich T, Pummer K, Berindan-Neagoe I, Perakis S, Schwarzenbacher D, Stotz M, Geiger A, Pichler M. Current insights into long non-coding RNAs in renal cell carcinoma. Int J Mol Sci. 2016;17(4):573.
22. Zlatian OM, Comanescu MV, Rosu AF, Rosu L, Cruce M, Gaman AE, Calina CD, Stredil V. Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. Rom J Morphol Embryol. 2015;56(1):175–81.
23. Janosi SL, Batani A, Ile MA, Tampa M, Georgescu SR, Zurac S, Boda D, Ianosi NG, Neagoe D, Calina D, et al. Non-invasive imaging techniques for the in vivo diagnosis of Bowen's disease: three case reports. Oncol Lett. 2019;17(5):4094–101.
24. Braicu C, Catana C, Galin A-G, Berindan-Neagoe I. NCRNA combined therapy as future treatment option for cancer. Curr Pharm Des. 2014;20(42):6565–74.
25. Braicu C, Zimta A-A, Harangus A, Iurca I, Irimie A, Coza O, Berindan-Neagoe I. The function of non-coding RNAs in lung cancer tumorigenesis. Cancers. 2019;11(5):605.
26. Braicu C, Pilecki V, Irimie A, Berindan-Neagoe I. p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol Cell Biochem. 2013;381(1–2):261–8.
27. Ganapathi MK, Jones WD, Sehoulj I, Michener CM, Braicu IE, Norris EJ, Biscotti CV, Vazni SA, Ganapathin RN. Expression profile of COL2A1 and the pseudogene SLCA6A1P predicts tumor recurrence in high-grade serous ovarian cancer. Int J Cancer. 2016;138(3):679–88.
28. Fouda YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017;7(5):1016–36.
29. Sani TA, Mohammadpour E, Mohammad A, Memariani T, Yazdi MV, Rezaee R, Calina D, Docea AO, Goumenou M, Etemad L, et al. Cytotoxic and apoptogenic properties Of Dracaena cinnabari aerial part differential fractions on calu-6 and mehr-80 lung cancer cell lines. Farmacia. 2017;65(2):189–99.
30. Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015;5(4):a06098.
31. Shottt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol. 2012;4(12):a009829.
32. Ungefroren H. Autocrine TGF-β in cancer: review of the literature and caveats in experimental analysis. Int J Mol Sci. 2021;22(2):1937.
33. Wei P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52.
35. Pylayeva-Gupta Y, Graboeck B, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761–74.

36. Debela DT, Muzauz SG, Heraro KD, Ndalama MT, Msele BW, Haile DC, Kitui SK, Manyazewel T. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370–2050312121034370.

37. Silk JD, Abbott RJM, Adams KJ, Bennett AD, Brett S, Cornforth TV, Crossland KL, Figueroa DJ, Jing J, O'Connor C, et al. Engineering cancer antigen-specific T cells to overcome the immunosuppressive effects of TGF-B. J Immunol. 2022;208(1):169–80.

38. Ali ES, Sahu UU, Villa E, O'Hara BP, Gao P, Beaudet C, Wood AW, Asara JM, Ben-Sahra I. ERK Phosphorylates PFA5 to mediate posttranslational control of de novo purine synthesis. Mol Cell. 2020;78(6):1178–1191. e1176.

39. Lee S, Rauch J, Kolch W. Targeting MAPK signalling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci. 2020;21(3):1102.

40. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50–83.

41. Sharifi-Rad J, Quispe C, Butnariu M, Rotariu LS, Sytar O, Sestito S, Raposselli S, Agrawal KK, Ashraf M, et al. Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. Cancer Cell Int. 2021;21(1):318–318.

42. Taheri Y, Quispe C, Herrera-Braico J, Sharifi-Rad J, Ezzat SM, Merghany RM, Shaheen AS, Al-Mamary M, Sestito S, et al. Urtica dioica Lepidium sativum L. seeds: a new source of natural products as potential inhibitors of SARS-CoV-2 using molecular docking simulation. Chin Integr Med. 2021. https://doi.org/10.1007/s11515-021-01337-7.

43. Hossain R, Quispe C, Saikat ASM, Jain D, Habib A, Janmeda P, Islam MT, et al. Amentoflavone, new hope against SARS-CoV-2: an outlook through its scientific records and an in silico study. Pharmacogn Res. 2021. https://doi.org/10.5530/prs.13.3.7.

44. Rajib H, Muhammad Torequl I, Pranta R, Divya J, Abu Sair Mohammad S, Lutfun N, Annapam Das T, Satyajit S, Seyed Abdulmajid A, Al-Marhoon ZM, et al. Effect of flavonoids on proliferation and invasion of MCF-7 cells. J Cell Physiol. 2021;237(5):4255–65.

45. Hossain R, Quispe C, Saikat ASM, Jain D, Habib A, Janmeda P, Islam MT, et al. Inhibitory effect of caffeic acid phenethyl ester on proliferation and migration of prostate cancer cells by regulating AKT, ERK1/2, and JNK MAPK cell signaling cascades. J Cell Physiol. 2017;232(6):1428–40.

46. Kim GD. Kaempferol inhibits angiogenesis by suppressing HIF-1 alpha and VEGFR2 activation via ERK/p38 MAPK and PI3K/AKT signaling pathways in endothelial cells. Prev Nutr Food Sci. 2017;22(4):320–6.

47. Cui S, Wang J, Wu Q, Qian J, Yang C, Bo P. Genistein inhibits the growth and regulates the migration and invasion abilities of melanoma cells via the FAK/paxillin and MAPK pathways. Oncotarget. 2017;8(13):21674–91.

48. Malloy KM, Wang J, Clark LH, Fang Z, Sun W, Yin Y, Kong W, Zhou C, et al. Bae-Jump VL. Novelsoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways. Am J Transl Res. 2018;10(3):764–95.

49. Ge J, Liu Y, Li Q, Guo X, Gu L, Ma ZG, Zhou YP. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTor and activating p38-MAPK. Biomed Environ Sci. 2013;26(1):902–11.

50. Saleh B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokkou PV, Martins N, Sharifi-Rad J, et al. A double-edged sword in health and disease: dual role of ERK2. Cancer Lett. 2019;40(3):91.

51. Zhu J, Yu W, Liu B, Wang Y, Shao J, Wang J, Xia K, Liang C, Fang W, Zhou C, et al. Escin interacts with caspase-dependent apoptosis and autophagy through its ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis. 2017;8(10):e3131.

52. Aldonbza MB, Hong JY, Bae SJ, Song J, Kim WK, Oh J, Shin Y, Lee SH, Lee SK. Suppression of MAPK signaling and reversal of mTOR-dependent MDRI-associated multidrug resistance by 21alpha-methylpolymethanol in lung cancer cells. PLoS ONE. 2015;10(6):e0127841.

53. Luo W, Liu X, Sun W, Lu JJ, Wang Y, Chen X, Toosendanian, a natural product, inhibited TGF-β1-induced epithelial-mesenchymal transition through ERK/Snail pathway. Phytother Res. 2018;32(10):2009–20.

54. Shao J, Wang C, Li L, Liang H, Dai J, Ling X, Tang H. Luteolin inhibits proliferation and promotes intrinsic and extrinsic pathway-mediated apoptosis involving MAPK and mTOR signaling pathways in human cervical cancer cells. Int J Mol Sci. 2018;19(6):1664.

55. Liang RR, Zhang S, Qi JA, Wang ZD, Li J, Liu P, Huang C, Le XF, Yang J, Li ZF. Preferential inhibition of hepatocellular carcinoma by the flavonoid Basaclein through blocking MEK-ERK signaling. Int J Oncol. 2012;41(3):969–74.

56. Zhang XJ, Jia SS, Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-kappaB/mTOR and ERK1/2 signaling pathways. Biomed Pharmacother. 2016;83:1164–74.

57. Lim W, Park S, Bazer FW, Song G. Naringenin-induced apoptotic cell death in prostate cancer cells is mediated via the PI3K/AKT and MAPK signaling pathways. J Cell Biochem. 2017;118(S):1118–31.

58. Mao J, Yang H, Cui T, Pan P, Kabir N, Chen D, Ma L, Chen X, Chen Y, Yang Y. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. Eur J Pharmacol. 2018;832:39–49.

59. Jain D, Murti Y, Khan WU, Hossain R, Hossain MN, Agravalk SK, Ashraf RA, Islam MT, Janmeda P, Taheri Y, et al. Roles of therapeutic bioactive compounds in hepatoellular carcinoma. Oxid Med Cell Longev. 2021;2021:9068850.

60. Qi N, Chen H, Ok Kim M, Luber BA, Bode AM, Dong Z. Taxifolin suppresses UV-induced skin carcinogenesis by targeting EGF and PI3K. Cancer Prev Res (Phila). 2012;5(9):1103–14.

61. Kang HM, Park BS, Kang HH, Park HR, Yu SB, Kim JR. Delphinidin induces apoptosis and inhibits epithelial-to-mesenchymal transition via the ERK/p38 MAPK-signaling pathway in human osteosarcoma cell lines. Environ Toxicol. 2018;33(6):640–9.

62. Lin M, Bi H, Yan Y, Huang W, Zhang G, Zhang G, Tang S, Liu Y, Zhang L, Ma J, et al. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Oncotarget. 2017;8(14):2346–57.
73. Singh VJ, Sharma B, Chawla PA. Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents. Bioorg Chem. 2021;114:105161.

74. Pi J, Jiang J, Cai H, Yang F, Jin H, Yang P, Cai J, Chen ZW. GE11 peptide conjugated selenium nanoparticles for EGFR targeted ondorni delivery to achieve enhanced antircancer efficacy by inhibiting EGF-R-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. Drug Deliv. 2017;24(1):1549–64.

75. Lev-Ari S, Starr A, Karauza V, Loewe V, Greif J, Fenig E, Aderka D, Ben-Yosef R. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGR and inhibition of Erk1/2 activity. Anticancer Res. 2006;26(6):4423–40.

76. Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D, Zheng Q. Licochalcone A induced in human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways. Sci Rep. 2015;5:10336.

77. Pan C, Hu Y, Li J, Wang Z, Huang J, Zhang S, Ding L. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer. PLoS ONE. 2014;9(8):e104459.

78. Zhang M, Cai S, Zuo B, Gong W, Tang Z, Zhou D, Weng M, Qin Y, Wang S, Liu J, et al. Antitumor induced galbladder cancer senescence through modulating epidermal growth factor receptor pathway. Tumorumour Biol. 2017;39(5):1010248317698359.

79. Lee CH, Ying TH, Chou HL, Hsieh SC, Wen SH, Chou RR, Hsieh YH. Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells. Oncotarget. 2017;8(29):47425–39.

80. Mi Jeong S, Davaatseren M, Kim W, Sung Kwang P, Kim SH, Haeng H. Polier G, Neumann J, Thuaud F, Ribeiro N, Gelhaus C, Schmidt H, Giaisi M, Koehler R, Muller WW, Proksch P, et al. The natural antitumor compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting ERK2 in lung cancer. Oncotarget. 2019;10(3):10886–94.

81. Asami Y, Kakeya H, Komi Y, Kojima S, Nishikawa K, Beeke B, Neckers L, Osada H, Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activation. Cancer Sci. 2008;99(9):1853–8.

82. Polier G, Neumann J, Thuaud F, Ribeiro N, Gelhaus C, Schmidt H, Giaisi M, Koehler R, Muller WW, Proksch P, et al. The natural antitumor compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting ERK2 in lung cancer. Oncotarget. 2019;10(3):10886–94.

83. Zhao A, Lee SH, Mojena M, Jenkins R, Patrick DR, Huber HE, Goetz MA, Hensens O, Zink DL, Vilella D, et al. Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK. J Antibiot. 1999;52(12):1086–94.

84. Lee C-O, Lee M-H, Yoo S-M, Choi K-I, Song J-H, Jeon H, Myung Sunny K, Kim YS, Dae Young K. Vitisin A suppresses Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells. Oncotarget. 2017;8(29):47425–39.

85. Jeon S, Kim M-M. Tomatidine inhibits cell invasion through the negative regulation of autophagy via the AKT/mTOR signaling pathway to improve cognitive dysfunction in rats with chronic cerebral hypoperfusion. Front Neurosci. 2019;13:859.

86. Zhao W, Lao Y, Liu Y, Niu J, Xiao Z, Arulselvan P, Shen J. Escin induces apoptosis in ovarian cancer cell line by triggering S-phase cell cycle arrest and p38 MAPK/ERK pathway inhibition. J King Saud Univ Sci. 2022;34(1):101644.

87. Munakarmi S, Chand L, Shinn HB, Yoon B-S, Park HR, Jeong YI. Antitumor effects of Punica granatum on prostate cancer through regulation of apoptosis, migration, and invasion. Oncol Rep. 2020;44(6):2537–46.

88. Fan W, Fan L, Wang Z, Yang P, Limonoids from the genus Melia (Meliaceae): phytochemistry, synthesis, bioactivities, pharmacokinetics, and toxicology. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2021.795565.

89. Rizzo VL, Levine CB, Waskshlag J. The effects of salsalate on canine osteosarcoma proliferation and invasion. Vet Comp Oncol. 2017;15(3):718–30.

90. Revol J, Lebreton P, Le Donchere M, Vickers D, O'Reilly KM, Funkenstein AC, et al. Potential anti-platelet aggregation agents: from biochemistry to health promoting abilities. Crit Rev Food Sci Nutr. 2021. https://doi.org/10.1080/10408398.2021.1924612.

91. Borah N, Gunawan D, Toh SL, McDonnell S, Van Slambrouck S. 5,6,7,3′,4′,5′-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle. Int J Oncol. 2017;51(6):1865–93.

92. Sharifi-Rad J, Quispe C, Durazzo A, Lucarin M, Souto EB, Santini A, Imran M, Moussa Ay, Mostafa NM, El-Shazly M, et al. Resveratrol: biotechnological applications: enlightening its antimicrobial and antioxidant properties. J Herb Med. 2022;32:100550.

93. Wang N, He J, Pan C, Wang J, Ma M, Shi X, Xu Z. Resveratrol activates autophagy via the AKT/mTOR signaling pathway to improve cognitive dysfunction in rats with chronic cerebral hypoperfusion. Front Neurosci. 2019;13:859.
108. Hossain R, Quispe C, Herrera-Bravo J, Beltrán JF, Islam MT, Shaheen S, Cruz-Martins N, Martorell M, Kumar M, Sharifi-Rad J, et al. Neurobiological promises of the bitter diterpene lactone andrographolide. Oxic Med Cell Longev. 2022;2022:3079577.

109. Guerra B, Insinger O-G. Natural compounds and derivatives as Ser/Thr protein kinase modulators and inhibitors. Pharmaceuticals [Basel]. 2019;12(1).

110. Lin HH, Robertson KL, Lellupitiyage Don SS, Taylor SR, Farkas ME. Chapter six - chemical modulation of circadian rhythms and assessment of cellular behavior via indirubin and derivatives. In: Chenoweth DM, editor. Methods in enzymology, vol. 639. Cambridge: Academic Press; 2020.

111. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol. 2004;130(1):627–35.

112. Abdallah QA, Fortwendel JR. Exploration of Aspergillus fumigatus Ras pathways for novel antifungal drug targets. Front Microbiol. 2015;6:128.

113. Song J-H, Lee C-J, An H-J, Yoo S-M, Kang HC, Lee YJ, Kim KD, Kim DJ, Lee HS, Cho Y-Y. Magnolining targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells. Mol Cancinog. 2019;58(1):88–101.

114. Calina D, Buga AM, Mitroi M, Bluha A, Canuntu C, Scheau C, Bouyahya A, El Omari N, El Menyiy N, Docea AO. The treatment of cognitive, behavioural and motor impairments from brain injury and neurodegenerative diseases through cannabinoid system modulation-evidence from in vivo studies. J Clin Med. 2020;9(9):28.

115. Sharifi-Rad J, Quispe C, Herrera-Bravo J, Martorell M, Sharopov F, Turner TB, Kurt B, Lankatllake C, Docea AO, Moreira AC, et al. A pharmacological perspective on plant-derived bioactive molecules for epilepsy. Neurochem Res. 2021. https://doi.org/10.1007/s11064-021-03376-0.

116. Sharifi-Rad J, Quispe C, Kumar M, Akram M, Amin M, Isqbal M, Koirala N, Sytar O, Kregel D, Nicola S, et al. Hyssopus essential oil: an update of its phytochemistry, biological activities, and safety profile. Oxic Med Cell Longev. 2022;2022:8442734.

117. Islam MT, Quispe C, El-Kersh DM, Shill MC, Bhardwaj K, Bhardwaj P, Sharifi-Rad J, Martorell M, Hossain R, Al-Harrasi A, et al. A literature-based update on Benincasa hispida (Thunb.) Cogn.: traditional uses, nutraceutical, and phytopharmaceutical profiles. Oxid Med Cell Longev. 2021;2021:6349041.

118. Hossain R, Quispe C, Herrera-Bravo J, Islam MS, Sarkar C, Islam MT, Martorell M, Cruz-Martins N, Al-Harrasi A, Al-Rawahi A, et al. Lasia sponica chemical composition and therapeutic potential: a literature-based review. Oxid Med Cell Longev. 2021;2021:1602437.

119. Salehi B, Quispe C, Chamkhili, El Omari N, Balahbib A, Sharifi-Rad J, Bouyahya A, Akram M, Isqbal M, Docea AO, et al. Pharmacological properties of chalcones: a review of preclinical including molecular mechanisms and clinical evidence. Front Pharmacol. 2021;11:592654–592654.

120. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 2009;10(3):194–200.

121. Safarzadeh E, Sandogchid Shotorbani S, Baradanar B. Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull. 2014;4(Suppl 1):421–7.

122. Sharifi-Rad J, Kamiloglu S, Yeskalievba B, Beyati A, Alfred MA, Salehi B, Calina D, Docea AO, Imran M, Kumar NVA, et al. Pharmacological activities of psoralidin: a comprehensive review of the molecular mechanisms of action. Front Pharmacol. 2020;11:11.

123. Baba Y, Kato Y, Deguen L, a novel anti-tumorigenic agent in human esophageal squamous cell carcinoma. EBioMedicine. 2017;26;10.

124. Ma C, Peng Y, Li H, Chen W. Orgon-on-a-chip: a new paradigm for drug development. Trends Pharmacol Sci. 2021;42(2):119–33.

125. Roskoski Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res. 2021;165: 105463.

126. Shepherd C, Puzanov I, Sosman JA. B-RAF inhibitors: an evolving role in the treatment of melanoma. Curr Oncol Rep. 2010;12(3):146–52.

127. Singh CV, Gaban P. Extreme endpoints: radiation resistance microbial reserves and therapeutic implications. J Appl Microbiol. 2011;110(4):851–61.

128. Salehi B, Sharifi-Rad J, Capanoglu E, Adiar N, Catalayka G, Shaheen S, Jaffer M, Gini L, Suyal R, Lugan AK, et al. Cucurbita plants: from farm to industry. Appl Sci-Basel. 2019;9(16):21.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.